Business Description
NKGen Biotech Inc
NAICS : 541714
SIC : 2834
ISIN : US65488A1016
Description
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Equity-to-Asset | -4.46 | |||||
| Debt-to-Equity | -0.4 | |||||
| Debt-to-EBITDA | -0.33 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 69.58 | |||||
| 9-Day RSI | 65.15 | |||||
| 14-Day RSI | 58.14 | |||||
| 6-1 Month Momentum % | -81.04 | |||||
| 12-1 Month Momentum % | -90.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.02 | |||||
| Quick Ratio | 0.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -74.5 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -479.36 | |||||
| ROIC % | -73.21 | |||||
| ROC (Joel Greenblatt) % | -590.84 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.49 | |||||
| EV-to-EBITDA | -0.5 | |||||
| EV-to-FCF | -1.96 | |||||
| Earnings Yield (Greenblatt) % | -204.08 | |||||
| FCF Yield % | -152.39 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NKGN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NKGen Biotech Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -5.08 | ||
| Beta | 0 | ||
| Volatility % | 182.12 | ||
| 14-Day RSI | 58.14 | ||
| 14-Day ATR ($) | 0.060832 | ||
| 20-Day SMA ($) | 0.30241 | ||
| 12-1 Month Momentum % | -90.77 | ||
| 52-Week Range ($) | 0.2026 - 4.06 | ||
| Shares Outstanding (Mil) | 35.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NKGen Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NKGen Biotech Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
NKGen Biotech Inc Frequently Asked Questions
What is NKGen Biotech Inc(NKGN)'s stock price today?
The current price of NKGN is $0.40. The 52 week high of NKGN is $4.06 and 52 week low is $0.20.
When is next earnings date of NKGen Biotech Inc(NKGN)?
The next earnings date of NKGen Biotech Inc(NKGN) is 2024-12-31 Est..
Does NKGen Biotech Inc(NKGN) pay dividends? If so, how much?
NKGen Biotech Inc(NKGN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers